Correlation Between Viridian Therapeutics and DBV Technologies

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Viridian Therapeutics and DBV Technologies at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Viridian Therapeutics and DBV Technologies into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Viridian Therapeutics and DBV Technologies, you can compare the effects of market volatilities on Viridian Therapeutics and DBV Technologies and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Viridian Therapeutics with a short position of DBV Technologies. Check out your portfolio center. Please also check ongoing floating volatility patterns of Viridian Therapeutics and DBV Technologies.

Diversification Opportunities for Viridian Therapeutics and DBV Technologies

-0.26
  Correlation Coefficient

Very good diversification

The 3 months correlation between Viridian and DBV is -0.26. Overlapping area represents the amount of risk that can be diversified away by holding Viridian Therapeutics and DBV Technologies in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on DBV Technologies and Viridian Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Viridian Therapeutics are associated (or correlated) with DBV Technologies. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of DBV Technologies has no effect on the direction of Viridian Therapeutics i.e., Viridian Therapeutics and DBV Technologies go up and down completely randomly.

Pair Corralation between Viridian Therapeutics and DBV Technologies

Assuming the 90 days trading horizon Viridian Therapeutics is expected to generate 0.81 times more return on investment than DBV Technologies. However, Viridian Therapeutics is 1.23 times less risky than DBV Technologies. It trades about -0.02 of its potential returns per unit of risk. DBV Technologies is currently generating about -0.12 per unit of risk. If you would invest  2,256  in Viridian Therapeutics on August 30, 2024 and sell it today you would lose (81.00) from holding Viridian Therapeutics or give up 3.59% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Viridian Therapeutics  vs.  DBV Technologies

 Performance 
       Timeline  
Viridian Therapeutics 

Risk-Adjusted Performance

10 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Viridian Therapeutics are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unsteady basic indicators, Viridian Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point.
DBV Technologies 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days DBV Technologies has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unsteady performance, the Stock's basic indicators remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors.

Viridian Therapeutics and DBV Technologies Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Viridian Therapeutics and DBV Technologies

The main advantage of trading using opposite Viridian Therapeutics and DBV Technologies positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Viridian Therapeutics position performs unexpectedly, DBV Technologies can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DBV Technologies will offset losses from the drop in DBV Technologies' long position.
The idea behind Viridian Therapeutics and DBV Technologies pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.

Other Complementary Tools

Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences